June 5, 2020

The Niche

Knoepfler lab stem cell blog

Ocata

2 min read

Stem cell news is always burbling up, sometimes right there in front of us on the web and other times via networks of people. Astellas news. Some may remember there used to be this pioneering stem cell biotech called ACT, which then became Ocata, and finally was acquired by the big company Astellas. One of their areas of focus was on using pluripotent stem cells for macular degeneration. The driving scientific force was (and is) Dr. Robert Lanza. About a year ago I had …Read More

3 min read

Do stem cells for vision loss offer real hope? I believe so, but it’s a long road and must be done right. A new paper in this area generated some buzz on top of an earlier recent pub (mentioned in this post) just a week or so ago about the potential of stem cells for vision loss. The new paper is entitled, “A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration” and is Kashani, et al. They generated special eye cells called retinal …Read More

4 min read

Each year I make a list of predictions for the year to come for the stem cell and regenerative medicine field. Then about a year later I grade myself on how I did as that year winds down. Here’s how I did in 2016. For 2017, late in 2016 I made 20 stem cell predictions. Let’s now see how I did. I was wrong on 6 out of the 20 predictions and mostly right on the rest with some others in the middle that I colored …Read More

3 min read

Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions. You can see below links to these predictions for past years, which sometimes seems rather far removed from today and in other cases strike me as strangely apropos of …Read More

3 min read

Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, which looks to be a dramatic year in the field of stem cells and regenerative medicine. The Score Card on 2016 Predictions Another stem cell biotech acquisition by pharma …Read More

4 min read

The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to polls, has been the leading backer of the REGROW Act. Kirk has been more in the news of late due to extremely controversial Trump-like comments he made about his …Read More